Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 4 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Classical hematology 1

Conditions

Venous Thromboembolism 3Neoplasms 2Venous Thrombosis 1Upper Extremity Deep Vein Thrombosis 1Thrombosis 1Multiple Myeloma 1Head and Neck Neoplasms 1Fibrosis 1Catheter-Related Infections 1Carcinoma, Hepatocellular 1

Interventions

Dexamethasone 11Lenalidomide 10Bortezomib 9Zoledronic Acid 8ixazomib 4daratumumab 4Melphalan 4tocilizumab 3Thalidomide 3Cyclophosphamide 3pomalidomide 2carfilzomib 2Prednisone 2Kyphoplasty 2Filgrastim 2Doxorubicin 2Calcium Dobesilate 2zanubrutinib 1talquetamab 1pegylated granulocyte colony-stimulating factor 1montelukast 1isatuximab 1ibrutinib 1exifone 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1apixaban 1Vaccination 1Thiotepa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Multiple Myeloma × apixaban × Clear all
NCT02958969 2019-12-17

Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma

Dana-Farber Cancer Institute

Phase 4 Completed
50 enrolled 5 charts
Classical hematologyPlasma cell

Multiple Myeloma, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡